HARNESSING THE POWER OF THE IMMUNE SYSTEM
Syncromune’s unique technology is being developed to optimize anti-tumor responses by combining tumor lysis with fixed-dose combination intratumoral immunotherapy
An Intratumoral Combination Approach to Overcoming Tumor Complexity
The Syncrovax™ platform is a next generation cancer therapy that is designed to optimize anti-tumor responses via a combination approach of tumor lysis and fixed-dose intratumoral immunotherapy with multiple active ingredients. This new approach to treating cancer aims to overcome the immunosuppressive characteristics of metastatic cancers and the limitations of current cancer therapies.
In addition, Syncrovax™ is being developed to utilize a low dose of immunotherapeutic agents with a high concentration which can reduce the combined toxicities observed when multiple drugs of the same classes are combined and administered systemically.
Disclaimers: The content on this website is intended for US healthcare professionals only. The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the US Food and Drug Administration.